Harvey WH - Search Results

1

The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.

Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ. Gandara DR, et al. Among authors: harvey wh. Semin Oncol. 1992 Aug;19(4 Suppl 10):67-71. Semin Oncol. 1992. PMID: 1387253 Clinical Trial.

2

Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.

Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. Gandara DR, et al. Among authors: harvey wh. Eur J Cancer. 1993;29A Suppl 1:S35-8. doi: 10.1016/s0959-8049(05)80259-x. Eur J Cancer. 1993. PMID: 8427724 Clinical Trial.

3

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G, et al. Hainsworth J, et al. J Clin Oncol. 1991 May;9(5):721-8. doi: 10.1200/JCO.1991.9.5.721. J Clin Oncol. 1991. PMID: 1826739 Clinical Trial.

4

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.

Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B. Hesketh PJ, et al. Among authors: harvey wh. J Clin Oncol. 1994 Mar;12(3):596-600. doi: 10.1200/JCO.1994.12.3.596. J Clin Oncol. 1994. PMID: 8120559 Clinical Trial.

5

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.

Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE. Beck TM, et al. Among authors: harvey wh. Ann Intern Med. 1993 Mar 15;118(6):407-13. doi: 10.7326/0003-4819-118-6-199303150-00002. Ann Intern Med. 1993. PMID: 8439113 Clinical Trial.

6

Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.

Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D, Wentz A. Beck TM, et al. Among authors: harvey wh. Cancer Invest. 1997;15(4):297-303. doi: 10.3109/07357909709039729. Cancer Invest. 1997. PMID: 9246149 Clinical Trial.

7

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.

Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR. Sondak VK, et al. Among authors: harvey wh. Anticancer Drugs. 1994 Apr;5(2):147-50. Anticancer Drugs. 1994. PMID: 8049497 Clinical Trial.

8

Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer.

Friess GG, Baikadi M, Harvey WH. Friess GG, et al. Among authors: harvey wh. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):681-4. Cancer Treat Rep. 1987. PMID: 3038313

9

Hepatoma/merbarone. A Southwest Oncology Group study.

Poplin EA, Tangen CM, Harvey WH, Macdonald JS. Poplin EA, et al. Among authors: harvey wh. Invest New Drugs. 1994;12(4):337-40. doi: 10.1007/BF00873051. Invest New Drugs. 1994. PMID: 7775137 Clinical Trial.

10

Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712.

Harvey WH, Fleming TR, Goodman PJ, Harvey JH, Rivkin SE, MacDonald JS. Harvey WH, et al. Invest New Drugs. 1993 Feb;11(1):45-6. doi: 10.1007/BF00873909. Invest New Drugs. 1993. PMID: 8394295 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters